Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by stockman6767on Jan 24, 2007 12:53pm
331 Views
Post# 12081465

Judge's ruling on HML for Catalyst

Judge's ruling on HML for CatalystThis ruling by the Judge, while a little short of my call for an outright auction of HML, serves nearly as well. It did not hand HML to Melynk, but did not knock him out of running should he up his bid. So effectively it is now a two man race. Hopefully the HML shareholders may now see a small glimmer of light. The G&M offered that perhaps the two would now get together and share HML. I hope that does not happen, as then we are back to one bidder. Unfortunately, in the short term, what is good for HML shareholders is bad for PLI shareholders, as this will undoubtedly extend by several months the uncertainty wrt to HML and further delay any royalty payments to PLI. However, in the long run this is favorable for PLI as well. Since I have shres both in HML and PLI I am torn between what I actually want to happen in the short term, but I tend toward the long term view as good for both.
Bullboard Posts